Literature DB >> 33629796

MicroRNA-370-3p shuttled by breast cancer cell-derived extracellular vesicles induces fibroblast activation through the CYLD/Nf-κB axis to promote breast cancer progression.

Zhaojun Ren1, Mengmeng Lv2, Qiao Yu3, Jun Bao4, Kexin Lou1, Xiujuan Li3.   

Abstract

Breast cancer is a malignancy arising in the mammary epithelial tissues. Recent studies have indicated the abundance of microRNAs (miRNAs) in extracellular vesicles (EVs), and their interactions have been illustrated to exert crucial roles in the cell-to-cell communication. The present study focused on investigating whether EV-delivered miR-370-3p affects breast cancer. Initially, the miR-370-3p expression pattern was examined in the cancer-associated fibroblasts (CAFs), normal fibroblasts (NFs), and cancerous cells-derived EVs. The relation of miR-370-3p to CYLD was assessed using luciferase activity assay. Afterwards, based on ectopic expression and depletion experiments in the MCF-7 breast cancer cells, we evaluated stemness, migration, invasion, and sphere formation ability, and EMT, accompanied with measurement on the expression patterns of pro-inflammatory factors and nuclear factor-kappa B (NF-κB) signaling-related genes. Finally, tumorigenesis and proliferation were analyzed in vivo using a nude mouse xenograft model. The in vitro experiments revealed that breast cancer cell-derived EVs promoted NF activation, while activated fibroblasts contributed to enhanced stemness, migration, invasion, as well as EMT of cancerous cells. In addition, EVs could transfer miR-370-3p from breast cancer cells to NFs, and EV-encapsulated miR-370-3p was also found to facilitate fibroblast activation. Mechanistically, EV-encapsulated miR-370-3p downregulated the expression of CYLD through binding to its 3'UTR and activated the NF-κB signaling pathway, thereby promoting the cellular functions in vitro and in vivo in breast cancer. Taken together, EVs secreted by breast cancer cells could carry miR-370-3p to aggravate breast cancer through downregulating CYLD expression and activating the NF-κB signaling pathway.
© 2021 Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  CYLD; NF-κB; extracellular vesicles; fibroblasts; highly metastatic breast cancer cells; miR-370-3p

Mesh:

Substances:

Year:  2021        PMID: 33629796     DOI: 10.1096/fj.202001430RR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  6 in total

1.  Hub genes associated with immune cell infiltration in breast cancer, identified through bioinformatic analyses of multiple datasets.

Authors:  Huanyu Zhao; Ruoyu Dang; Yipan Zhu; Baijian Qu; Yasra Sayyed; Ying Wen; Xicheng Liu; Jianping Lin; Luyuan Li
Journal:  Cancer Biol Med       Date:  2022-07-13       Impact factor: 5.347

Review 2.  Circulating miRNAs in Breast Cancer Diagnosis and Prognosis.

Authors:  Barbara Cardinali; Roberta Tasso; Patrizia Piccioli; Maria Chiara Ciferri; Rodolfo Quarto; Lucia Del Mastro
Journal:  Cancers (Basel)       Date:  2022-05-07       Impact factor: 6.575

3.  circITGA7 Acts as a miR-370-3p Sponge to Suppress the Proliferation of Prostate Cancer.

Authors:  Gang Luo; Guohao Li; Zhihua Wan; Yuanjie Zhang; Dong Liu; Yonglian Guo
Journal:  J Oncol       Date:  2021-12-31       Impact factor: 4.375

Review 4.  More than a Bubble: Extracellular Vesicle microRNAs in Head and Neck Squamous Cell Carcinoma.

Authors:  Wittaya Panvongsa; D Michiel Pegtel; Jens Voortman
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

Review 5.  Cancer-associated fibroblasts in breast cancer: Challenges and opportunities.

Authors:  Dengdi Hu; Zhaoqing Li; Bin Zheng; Xixi Lin; Yuehong Pan; Peirong Gong; Wenying Zhuo; Yujie Hu; Cong Chen; Lini Chen; Jichun Zhou; Linbo Wang
Journal:  Cancer Commun (Lond)       Date:  2022-04-28

Review 6.  Anti-Cancer Role and Therapeutic Potential of Extracellular Vesicles.

Authors:  Naoomi Tominaga
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.